BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Accepts IND for ConjuGon, Inc.'s C-1205 - Prevention of Urinary Tract Infections


4/24/2009 10:43:51 AM

April 23, 2009 Madison, WI—The U.S. Food and Drug Administration (FDA) completed its regulatory review of ConjuGon’s Investigational New Drug (IND) application for the prevention of Catheter-Associated Urinary Tract Infections (CAUTI).

This decision clears the way for ConjuGon to begin its proposed Phase Ib clinical trials of C-1205 in indwelling catheterized patients who experience urinary tract infections. ConjuGon plans to begin enrolling patients in the study later this year. “We are extremely pleased that the FDA has cleared our IND,” said ConjuGon’s COO Steve Watt, Ph.D. “Based on results from several previous studies, we have high hopes that C-1205 will help prevent bladder and other urinary tract infections (UTIs)” Watt said. “Normally, patients who are catheterized, such as those with spinal cord injuries or the disabled elderly, will experience several UTIs each year. With this product, our expectation is that the number of UTIs will be greatly reduced, treatment costs will be lowered, and patients’ quality of life will be increased.”

ConjuGon, Inc., based in Madison, WI, is a clinical-stage biopharmaceutical company developing novel antibacterial technologies using harmless bacteria as drugs. ConjuGon’s lead product, C-1205, uses bacterial interference technology to inhibit bladder infections in spinal cord injury patients and others with indwelling catheters. The active ingredient in the product has been previously tested in people for the prevention of urinary tract infections, and has been shown to be safe and effective.

“ConjuGon’s business strategy is to partner or sell drug candidates in its pipeline during Phase II human studies”, said Gary Greenwood, ConjuGon’s chairman and a founding partner of Rosetta Partners. “Approval of the IND for ConjuGon’s lead product is a significant step forward both for this product and for the company as a whole.” Rosetta Partners, based in Lake Forest, Illinois, is a private investment firm focused exclusively on biotechnology investments and is ConjuGon’s largest shareholder. For more information, please visit www.conjugon.com.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES